Tissue Regenix extends development deal with NHS

The new agreement will extend the scope of clinical development for Tissue Regenix’s decellularised human tissue-based devices.

Tissue will develop products in partnership with NHSBT, and the agreement will allow the York-based firm to speed up evaluation of human tissue-based devices.

Tissue will retain exclusive rights to commercialise any data generated from the trials. Initially its work will look at decellularised human skin and cardiology.

Tissue Regenix managing director Antony Odell said: “We are pleased to expand our successful partnership with NHSBT.

“The new agreement will enable us to fast-track the development of additional applications for our dCELL Dermis products.

“NHSBT has unparalleled relationships with the NHS clinical community and world-class development facilities and these will enable us to jointly address a range of significant clinical needs in a cost and time efficient manner”.

Head of Tissue Services at NHSBT, Helen Gillan, said: “We welcome the expansion of our partnership with Tissue Regenix. In a rapidly advancing field, we have the specialist facilities and the necessary high level scientific experience needed to deliver novel patient therapies.

“Currently, we have a clinical trial underway using decellularised human donor skin grafts in the treatment of chronic, non-healing wounds. Although it is a relatively new trial, it is already showing great promise.”